Markets:

Overview

News

Currencies

International

Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

11.64 +0.12 (+1.04%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 Next >

3 Russell 2000 Stocks with Warning Signs

November 13, 2025

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these...

Via StockStory

3 Stocks Under $50 We Steer Clear Of

November 11, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Via StockStory

Topics Artificial Intelligence Stocks

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

A Peek at Amneal Pharmaceuticals's Future Earnings ↗

August 04, 2025

Via Benzinga

3 Value Stocks We Find Risky

November 09, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Why Amneal (AMRX) Stock Is Up Today

October 31, 2025

Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 8.9% in the afternoon session after the company reported strong third-quarter financial results that surpassed expectations...

Via StockStory

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Q3 2025 Earnings: EPS Beats Estimates, Stock Surges on Raised Guidance ↗

October 30, 2025

Amneal Pharmaceuticals Q3 2025 earnings beat profit estimates, driving a stock surge. The company also raised its full-year guidance for EBITDA and EPS.

Via Chartmill

Topics Earnings

Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars

October 30, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.7% year on year to $784.5 million. The company’s...

Via StockStory

Amneal Earnings: What To Look For From AMRX

October 28, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Thursday before the bell. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

3 Cash-Producing Stocks with Questionable Fundamentals

October 27, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

3 of Wall Street’s Favorite Stocks We Find Risky

October 14, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗

October 09, 2025

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.

Via Benzinga

Topics Government World Trade

1 Small-Cap Stock with Competitive Advantages and 2 We Turn Down

October 09, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

3 Lesser-Known Healthcare Names With Major Upside in Store ↗

October 02, 2025

These are three healthcare stocks offering a compelling combination of secure business, strong fundamentals, and growth opportunity.

Via MarketBeat

Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops ↗

September 23, 2025

Amneal’s bimatoprost ophthalmic solution 0.01% is indicated for the reduction of high eye pressure in patients with certain eye conditions.

Via Stocktwits

3 Low-Volatility Stocks We Find Risky

September 15, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Topics Economy Government World Trade

Why Amneal (AMRX) Stock Is Up Today

September 11, 2025

Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 4.7% in the afternoon session after the company announced it received U.S. Food and Drug Administration (FDA) approval for...

Via StockStory

Topics Artificial Intelligence Economy

3 Hyped Up Stocks with Open Questions

September 04, 2025

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or...

Via StockStory

1 Cash-Producing Stock for Long-Term Investors and 2 We Turn Down

August 20, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Topics Bonds

Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Artificial Intelligence Economy

AMRX Q2 Deep Dive: New Product Launches and Specialty Momentum Shape Guidance

August 13, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) missed Wall Street’s revenue expectations in Q2 CY2025 as sales rose 3.2% year on year to $724.5 million. On the other hand, the company’s...

Via StockStory

Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know

August 12, 2025

A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed...

Via StockStory

Topics Bonds Economy Stocks

1 Value Stock to Keep an Eye On and 2 Facing Challenges

August 11, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

Amneal (AMRX) Q2 EPS Jumps 56% ↗

August 05, 2025

Via The Motley Fool

Topics Economy

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Mixed Q2 2025 Results: Earnings Beat, Revenue Miss ↗

August 05, 2025

Amneal Pharmaceuticals (AMRX) reported mixed Q2 2025 results, with EPS beating estimates but revenue missing. Shares dipped slightly as investors weighed strong profitability against softer sales....

Via Chartmill

Topics Earnings

Amneal (NASDAQ:AMRX) Misses Q2 Sales Targets

August 05, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell short of the market’s revenue expectations in Q2 CY2025 as sales rose 3.2% year on year to $724.5 million. On the other hand, the...

Via StockStory

Amneal Earnings: What To Look For From AMRX

August 03, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Tuesday before the bell. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence Government World Trade

Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks

July 28, 2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AMRX) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

Headline News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

Starting at $3.75/week.

Subscribe Today